GIMBHI’s daily mental health update — 9/17/26

💊 Quel Health launches as first telehealth company built around GLP-1s for addiction (Quel Health, PRWeb) — 09/08/26
TL;DR: Santa Fe-based Quel Health launched in 41 states with Caron Treatment Centers as founding partner, offering telemedicine for off-label GLP-1 use in substance use disorders based on emerging clinical evidence.

⚡ Flow Neuroscience launches FDA-approved at-home tDCS brain stimulation device for depression in US (Marion Webb, Medtech Insight) — 09/12/26
TL;DR: Sweden-based Flow Neuroscience launched its FL-100 prescription at-home tDCS device for moderate-to-severe depression in the US at $2,200 for the initial 10-week course after receiving FDA premarket approval.

🤝 Beacon Behavioral Partners adds Prime Psychiatry and Invicta, doubling Dallas-Fort Worth footprint (Beacon Behavioral Partners, GlobeNewswire) — 09/08/26
TL;DR: Plano-based Beacon Behavioral Partners added seven North Texas clinic locations through partnerships with Prime Psychiatry and Invicta Healthcare, expanding access to Spravato, TMS, and interventional psychiatry.

🏛️ HHS awards $383.4M for behavioral health, 988, and crisis response services (Cailey Gleeson, Fierce Healthcare) — 09/08/26
TL;DR: SAMHSA distributed $383.4M in grants, with $252M for the 988 Lifeline, suicide prevention, and mobile crisis services, $81.4M for substance use, and $50M for mental health initiatives.